Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer
Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2008, 26: 1135-1141. PMID: 18309949, DOI: 10.1200/jco.2007.14.3685.Peer-Reviewed Original ResearchConceptsOral serine/threonine kinase inhibitorCell lung cancerPFS ratesMetastatic NSCLCOverall survivalLung cancerEastern Cooperative Oncology Group performance statusSix-month PFS rateProgression-free survival ratesEpidermal growth factor inhibitorsSerine/threonine kinase inhibitorProtein kinase CKinase inhibitorsPrior systemic regimensMedian overall survivalPrimary end pointThird-line therapyPhase II trialGrowth factor inhibitorsTumor cell apoptosisMedian PFSStable diseaseCommon toxicitiesPrior therapySystemic regimens